[Experimental study of target-specific adriamycin nanoparticles in treating tongue squamous cell carcinoma].
This study was designed to explore the method for increasing the target-specific action of anticancer agent in treating tongue squamous cell carcinoma. 30 purebred New Zealand rabbits burdened with tongue squamous cell carcinoma were randomly divided into 2 groups. Group A was treated with adriamycin and group B treated with adriamycin nanoparticles, with 15 animals in each group. The adriamycin and poly (buty1-2-cyanoacrylate)-adriamycin nanoparticles (mean diameter 93.1 nm+/-11.7 nm) with 1 mg/ml in concentration were administered respectively to subjects through super-selective lingual arterial tuber. The dose was 2 mg/kg for each group. 1, 5 and 15 hours after administration, 5 subjects were sacrificed and the tongue, carcinoma in tongue tissue, heart, liver, spleen, kidney and plasma were examined through high performance liquid chromatography (HPLC) to identify the drug concentration. The data then underwent Student's t test. The drug concentration in the tongue and carcinoma in group B were significantly higher than those in group A (P<0.01). The drug concentration in heart, liver, spleen, kidney and plasma of group B were significantly lower than those of group A (P<0.01). The super-selective lingual arterial administration of adriamycin nanoparticles can reinforce the target-specific action of anticancer agent, increase the drug concentration within the lesion and decrease it in non-specific organs.